Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023

NEW YORK, July 15, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023

http://www.reportlinker.com/p02166741/Cymbalta-Major-Depressive-Disorder---Forecast-and-Market-Analysis-to-2023.html

Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Cymbalta (duloxetine) is an antidepressant that belongs to the SNRI class. It was developed by Eli Lilly and initially launched in the US market in 2004. Regulatory approvals followed in 2005 in the 5EU, 2007 in Australia, and 2010 in Japan.

Scope

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Cymbalta including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Cymbalta for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Cymbalta performance
- Obtain sales forecast for Cymbalta from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 11
3.2 Classification 13
3.3 Symptoms and Subtypes of Major Depressive Disorder 15
3.4 Prognosis 16
3.5 Quality of Life 16
4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Diagnosis 17
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 18
4.1.3 Clinical Practice 21
5 Competitive Assessment 26
5.1 Overview 26
6 Cymbalta (Duloxetine) 28
6.1 Overview 28
6.2 Efficacy 29
6.3 Safety 30
6.4 SWOT Analysis 31
6.5 Forecast 31
7 Appendix 33
7.1 Bibliography 33
7.2 Abbreviations 35
7.3 Methodology 37
7.4 Forecasting Methodology 37
7.4.1 Diagnosed MDD Patients 37
7.4.2 Percent of Drug-Treated Patients 37
7.4.3 General Pricing Assumptions 38
7.4.4 Individual Drug Assumptions 39
7.4.5 Generic Erosion 39
7.5 Physicians and Specialists Included in this Study 40
7.6 About the Authors 42
7.6.1 Analyst 42
7.6.2 Therapy Area Directors 42
7.6.3 Global Head of Healthcare 43
7.7 About GlobalData 44
7.8 Disclaimer 44


1.1
List of Tables


Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10) 14
Table 2: Subtypes of Major Depressive Disorder 15
Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria 17
Table 4: Treatment Guidelines for Major Depressive Disorder 19
Table 5: Most Prescribed Drugs for MDD by Class in the 7MM and Australia, 2013 21
Table 6: Leading Treatments for MDD, 2013 27
Table 7: Product Profile - Cymbalta 29
Table 8: Cymbalta SWOT Analysis, 2023 31
Table 9: Global MDD Sales Forecasts ($m) for Cymbalta, 2013-2023 32
Table 10: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 41

1.2
List of Figures

Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons 13
Figure 2: Disease Management Model for Major Depressive Disorder 23
Figure 3: Major Depressive Disorder Treatment Algorithm 25

Companies Mentioned



To order this report: Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023
http://www.reportlinker.com/p02166741/Cymbalta-Major-Depressive-Disorder---Forecast-and-Market-Analysis-to-2023.html



__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker